Dasatinib for the treatment of chronic myeloid leukemia

References

• Sawyers CL. Chronic myeloid leukemia. N. Engl. J. Med.340, 1330–1340 (1999).
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nager B et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell2, 117–125 (2002).
   PubMed Web of Science ®Google Scholar
• Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol.108, 180–202 (2002).
   PubMed Web of Science ®Google Scholar
• Mughal TI, Goldman JM. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? Front. Biosci.11, 198–208 (2006).
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.348, 994–1004 (2003).
   PubMed Web of Science ®Google Scholar
• Deininger M, O’Brien SG, Guilhot F et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood114 (2009) (Abstract 1126).
   Google Scholar
• Hochhaus A, O’Brien SG, Guilhot F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia23, 1054–1061 (2009).
   PubMed Web of Science ®Google Scholar
• Shah NP. Medical management of CML. Am. Soc. Hematol. Educ. Program371–375 (2007).
   PubMedGoogle Scholar
• Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science293, 876–880 (2001).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia16, 2190–2196 (2002).
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myleogenous leukemia cells to treatment with imatinib mesylate. Leukemia18, 401–408 (2004).
   PubMed Web of Science ®Google Scholar
• Larghero J, Leguay T, Mourah S et al. Relationship between elevated levels of the α 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem. Pharmacol.66, 1907–1913 (2003).
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Kreuzer KA, Na IK et al. Determination of α-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol. Dis.28, 75–85 (2002).
   PubMed Web of Science ®Google Scholar
• Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am. Soc. Hematol. Educ. Program183–187 (2005).
   PubMedGoogle Scholar
• Kantarjian HM, Talpaz M, O’Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood103, 2873–2878 (2004).
   PubMed Web of Science ®Google Scholar
• Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. Am. J. Health Syst. Pharm.64, S9–S15 (2007).
   Google Scholar
• Tyler T. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. Ann. Pharmacother.43, 920–927 (2009).
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science305, 399–401 (2004).
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Bleickardt E, Nicaise C, Paquette RL, Sawyers CL. Potent transient inhibition of BCR–ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: implications for patient management and drug development. Blood108 (2006) (Abstract 2166).
   Web of Science ®Google Scholar
• Sawyers CL, Shah NP, Kantarjian HM et al. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825, results from a Phase I dose escalation study. Blood104, (2004) (Abstract 1).
   Google Scholar
• Talpaz M, Shah NP, Kantarjian HM et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med.354, 2531–2541 (2006).
   PubMed Web of Science ®Google Scholar
• Sakamaki H, Ischizawa K, Taniwaki M et al. Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int. J. Hematol.89, 332–341 (2009).
   PubMed Web of Science ®Google Scholar
• Hocchaus A, Baccarani M, Deininger M et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia22, 1200–1206 (2008).
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Baccarani M, Cervantes F et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J. Clin. Oncol.26 (2008) (Abstract 7009).
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperly J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood109, 4143–4150 (2007).
   PubMed Web of Science ®Google Scholar
• Guilot F, Apperley JF, Kim DW et al. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180–005). Blood110 (2007) (Abstract 470).
   Web of Science ®Google Scholar
• Cortes J, Kim DW, Raffous E et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia22, 2176–2183 (2008).
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase 2 study. Blood110, 2309–2315 (2007).
   PubMed Web of Science ®Google Scholar
• Porkka K, Simonsson B, Dombret H et al. Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180–015). Blood110 (2007) (Abstract 2810).
   Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood109, 5143–5150 (2007).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Levy V et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized Phase 2 study (START-R). Cancer115, 4136–4147 (2009).
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol.26, 3204–3212 (2008).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, Kim DW et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood113, 6322–6329 (2009).
   PubMed Web of Science ®Google Scholar
• Saglio G, Hocchaus A, Goh YT et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a Phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer116, 3852–3861 (2010).
   PubMed Web of Science ®Google Scholar
• Lillly MB, Ottmann OG, Shah NP et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a Phase 3 study. Am. J. Hematol.85, 164–170 (2010).
   PubMed Web of Science ®Google Scholar
• Sprycel (dasatinib) prescribing information. Bristol-Myers Squibb Princeton, NJ, USA (2010).
   Google Scholar
• Cortes JE, Jones D, O’Brien S et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J. Clin. Oncol.28, 398–404 (2010).
   PubMed Web of Science ®Google Scholar
• Radich JP, Kopecky KJ, Kamel-Reid S et al. A randomized Phase II trial of dasatinib 100 mg vs. imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), the S0325 intergroup trial. Blood116 (2010) (Abstract LBA-6).
   Google Scholar
• Kantarjian H, Shah NP, Hocchaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.362, 2260–2270 (2010).
   PubMed Web of Science ®Google Scholar
• Shah N, Kantarjian HM, Hocchaus A et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in DASISION trial: 18-month follow up. Blood116 (2010) (Abstract 206).
   Google Scholar
• Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor induced platelet dysfunction in patients with chronic myeloid leukemia. Blood114, 261–263 (2009).
   PubMed Web of Science ®Google Scholar
• Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leukemia Res.33, 861–864 (2009).
   PubMed Web of Science ®Google Scholar
• Rousselot P, Boucher S, Etienne G et al. Pharmacokinetics of dasatinib as first line therapy in newly diagnosed CML patients (OPTIM dasatinib trial), correlation with safety and response. Blood116 (2010) (Abstract 3432).
   Google Scholar
• Saglio G, Hocchaus A, Cortes JE et al. Safety and efficacy of dasatinib versus imatinib by baseline cardiovascular comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP), analysis of the DASISION trial. Blood116 (2010) (Abstract 2286).
   Google Scholar
• Apperley JF, Cortes JE, Kim DW et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J. Clin. Oncol.27, 3472–3479 (2009).
   PubMed Web of Science ®Google Scholar
• Porkka K, Baccarani M, Hocchaus A et al. Occurrence, management, and outcomes in patients with pleural effusion during dasatinib treatment for chronic-phase chronic myeloid leukemia (CML-CP) in the first-line setting: analysis of the DASISION trial. Blood116 (2010) (Abstract 2282).
   Google Scholar
• Lee HY, Lee SJ, Ha B et al. Multicenter retrospective study on the development of peripheral lymphocytosis during second-line dasatinib therapy for chronic myeloid leukemia. Blood116 (2010) (Abstract 2275).
   Google Scholar
• Schiffer CA, Cortes JE, Saglio G et al. Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib. Blood116 (2010) (Abstract 358).
   Google Scholar
• Mustjoki S, Ekblom M, Arstila TP et al. Clonal expanstion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia23, 1398–1405 (2009).
   PubMed Web of Science ®Google Scholar
• Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood DOI: 10.1182/blood-2010–2007–294330 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Johnson FJ, Agrawal S, Burris H et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer116, 1582–1591 (2010).
   PubMed Web of Science ®Google Scholar
• EleyT, Luo FR, Agrawal S et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J. Clin. Pharmacol.49, 700–709 (2009).
   PubMed Web of Science ®Google Scholar